• An Anticancer C-Kit Kinase Inhibitor Is Reengineered To Make It More Active And Less Cardiotoxic 

      Fernandez, Ariel; Sanguino, Angela; Peng, Zhenghong; Ozturk, Eylem; Chen, Jianping; Crespo, Alejandro; Wulf, Sarah; Shavrin, Aleksander; Qin, Chaoping; Ma, Jianpeng; Trent, Jonathan; Lin, Yvonne; Han, Hee-Dong; Mangala, Lingegowda S.; Bankson, James A.; Gelovani, Juri; Samarel, Allen; Bornmann, William; Sood, Anil K.; Lopez-Berestein, Gabriel (Amer Soc Clinical Investigation Inc, 2007)
      Targeting kinases is central to drug-based cancer therapy but remains challenging because the drugs often lack specificity, which may cause toxic side effects. Modulating side effects is difficult because kinases are ...